Revolution starts here
Sartar Therapeutics Ltd. was established to advance a breakthrough discovery in cancer therapy. Using gene expression profiling, we found aberrantly high phosphodiesterase 3A (PDE3A) gene overexpression in gastrointestinal stromal tumors (GIST), other soft tissue sarcoma subtypes and subgroups of patients with different types of cancer. This discovery of a novel cancer target PDE3A represents potentially a significant leap in cancer therapy.
Innovative drugs
Sartar uses principles of precision medicine, drug repurposing and reformulation to provide efficacious cancer therapies faster to the global markets.
Sartar Therapeutics is developing a new precision cancer treatment, SAR003, for soft tissue sarcomas, SAR003 specifically targets phosphodiesterase 3A (PDE3A) -protein expressing tumours.
SAR003 is based on drug reformulation and repositioning of anagrelide, and has a long-acting profile that shows superior pharmacokinetic properties over oral administration, making it better tolerated and more convenient for use in therapy.
Read more
Sartar Team
Sartar is a company dedicated to developing novel personalised therapies for hard to treat cancers. Our experienced team has the passion and enthusiasm for innovation to fulfill the mission of developing drugs for patients without therapy options.
Read moreNews
Today is the international GIST Awareness Day!
Gastrointestinal stromal tumour (GIST) is a rare cancer that presents in various forms and can affect individuals of all ages. The prognosis for metastatic GIST is poor. All current targeted therapies rely on tyrosine kinase inhibitors, which control disease progression for a limited time before patients exhaust available treatment options. Moreover, pediatric, adolescent, wild-type, and […]
Read article
July is the sarcoma awareness month
Sarcomas are rare, difficult-to-diagnose, and hard-to-treat cancers that can affect people of any age, accounting for up to 20% of all adolescent cancers. These cancers originate from different tissue types, resulting in many subtypes, such as gastrointestinal stromal tumors (GIST), liposarcomas, and leiomyosarcomas. They often grow undetected until they reach an advanced stage. This highlights […]
Read article
Meet our CEO in LSX World Congress 2024!
Meet our CEO Mikael Maksimow in the LSX World Congress in London on 29-30 April 2024!
Read article